Academic Journal
Q1Oncogene
About Oncogene
Oncogene is a scholarly journal published by Springer Nature. SCImago 2025 places it in Q1 with an SJR of 2.474 and an H-index of 387.
Its listed coverage is 1987-2026 and its research categories include Cancer Research (Q1); Genetics (Q1); Molecular Biology (Q1). The 2025 dataset reports 389 documents and 7753 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Cancer-related Molecular Pathways, Epigenetics and DNA Methylation, RNA modifications and cancer, Ubiquitin and proteasome pathways, Cell death mechanisms and regulation, Cancer-related gene regulation.
Recent Research Articles
Latest publications matched automatically by ISSN.
ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression
Xinyi Huang, Jiayi Liu, Jiao Ren, Jupeng Yuan et al.
2026-09-04 · DOI: 10.1038/s41388-026-03966-8A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK–RAS mutations
Marija A. Zarocsinceva, Moosa Qureshi, Nicola K. Wilson, George Giotopoulos et al.
2026-09-04 · DOI: 10.1038/s41388-026-03964-wThe RNA-binding protein La/SSB is associated with HNSCC progression and TFAP2C/FSCN1-linked transcriptional regulation
Shixian Liu, Deshang Chen, Wentao Zhang, Hui Li et al.
2026-09-03 · DOI: 10.1038/s41388-026-03959-7The GSEC-encoded polypeptide GESP drives colorectal cancer tumorigenesis via NPM1-c-Myc-mediated repression of NDRG1
Yoshihiro Kawasaki, Tomoatsu Hayashi, Akane Kitta-Kunihiro, Lumi Negishi et al.
2026-09-01 · DOI: 10.1038/s41388-026-03958-8Neuromedin U ‘innervation’ reprograms myeloid immunosuppression in neuroendocrine prostate cancer
Michela Perego, Jozef Madzo, Andrew V. Kossenkov, F. Cansu Atilgan et al.
2026-09-01 · DOI: 10.1038/s41388-026-03969-5Frequently amplified SHANK2 promotes esophageal squamous cell carcinoma progression through the DVL/YAP axis
Cuicui Wang, Wei Zhao, Man Li, Min He et al.
2026-08-31 · DOI: 10.1038/s41388-026-03974-8POC1A promotes the proliferation, metastasis and stemness of bladder cancer by stabilizing BMI1 via USP7
Houyi Wei, Renran Bai, Jianmin Liu, Lei Lyu et al.
2026-08-31 · DOI: 10.1038/s41388-026-03973-9DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling
Yuanqiao Zhao, Zhuo Xing, Mengmeng Wang, Liangmin Fu et al.
2026-08-29 · DOI: 10.1038/s41388-026-03967-7Correction: E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer
Alexander M. Minikes, Yu Song, Yan Feng, Changhwan Yoon et al.
2026-09-29 · DOI: 10.1038/s41388-026-03963-xSEC14L2 contributes to tumor progression by enhancing USP5-driven RBM3 deubiquitination in pancreatic ductal adenocarcinoma
Zengyu Feng, Kai Qin, Haocheng Yu, Chuanshuai Lin et al.
2026-08-26 · DOI: 10.1038/s41388-026-03968-6Decitabine suppresses triple-negative breast cancer by disrupting DNMT1 liquid-liquid phase separation and synergizes with G9a inhibition
Meilin Hu, Haojie Peng, Guochang Qiu, Sen Liu et al.
2026-08-26 · DOI: 10.1038/s41388-026-03971-xGenome-wide CRISPR screens identify an RXR–MYLIP–LDLR axis regulating BH3 mimetic sensitivity in peripheral T-cell lymphomas
Keito Yokoyama, Masahiro Chiba, Norio Takei, Keito Suto et al.
2026-08-25 · DOI: 10.1038/s41388-026-03970-yCholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation
Wenqi Xu, Shuhan Liu, Longlong Sun, Yao Bi et al.
2026-08-21 · DOI: 10.1038/s41388-026-03961-zEpithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1
Erdogan Pekcan Erkan, Emmi Hämäläinen, Julia Kolikova, Tiia Nikupaavola et al.
2026-08-21 · DOI: 10.1038/s41388-026-03957-9PTEN-AKT2 regulates mixed lineage liver cancer development and sensitizes cancer cells to TGFβ treatment
Qi Tang, Ielyzaveta Slarve, Jingyu Chen, Ni Zeng et al.
2026-08-20 · DOI: 10.1038/s41388-026-03960-0Tumor-derived PTX3 drives an immunosuppressive myeloid landscape and inhibits CD8 T cell-mediated anti-tumor immunity via PI3K-dependent signaling
Mohamed Y. Zaky, Monika Vashisht, Mohammad A. I. Al-Hatamleh, Karen Siddoway et al.
2026-08-19 · DOI: 10.1038/s41388-026-03936-0The Inv(16) Oncogene CBFB::MYH11 is Required for the Survival of Leukemia Cells in the Blood and Spleen, but not the Bone Marrow
Sipra Panda, Yiqian Wang, Venkatasai Rahul Dogiparthi, Michelle Becker et al.
2026-08-17 · DOI: 10.1038/s41388-026-03956-wImbalanced p53–RB signaling triggers cGAS–STING–mediated immune activation in early oral cancer development
Zichao Lu, Yasuhiro Mouri, Wenhua Shao, Akihiro Yasue et al.
2026-08-15 · DOI: 10.1038/s41388-026-03962-yInhibition of PINK1/Parkin-mediated mitophagy enhances the susceptibility of breast cancer to cuproptosis
Chaoyi Tang, Ka Su, Zexu Zhan, Rongzhi Huang et al.
2026-08-13 · DOI: 10.1038/s41388-026-03945-zClinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs
Guanglin Niu, Catharina Hagerling
2026-08-12 · DOI: 10.1038/s41388-026-03944-0Reviews
Community Reviews
Version History
September 8, 2026 at 12:09 am
September 8, 2026